Want to see CLVT full AI Analyst Report?
CLVT Stock Chart & Stats
$2.13
$0.27(12.68%)
At close: 4:00 PM EDT
$2.13
$0.27(12.68%)
Day’s Range― - ―
52-Week Range$1.66 - $4.56
Previous Close$2.4
Volume9.18M
Average Volume (3M)4.90M
Market Cap
$1.27B
Enterprise Value$5.42K
Total Cash (Recent Filing)$217.70M
Total Debt (Recent Filing)$4.26B
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 10, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding639,664,000
10 Day Avg. Volume4,496,965
30 Day Avg. Volume4,903,935
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.46
Price to Sales (P/S)0.92
P/FCF Ratio6.16
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.93Price Target Upside37.72% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)0.75
Revenue Forecast (FY)$2.33B
Bulls Say, Bears Say
Bulls Say
Cash GenerationClarivate generates stable, positive operating cash flow and has shown a step-up in free cash flow recently. Durable cash generation supports debt paydown, opportunistic debt repurchases, and reinvestment in product development, increasing financial flexibility over the next several quarters.
Higher Recurring Revenue MixThe planned LS&H divestiture materially lifts the recurring-subscription mix to ~92%, improving revenue predictability and retention economics. A higher recurring base reduces exposure to volatile transactional sales, making cash flows and margin planning more durable over the medium term.
Margin Expansion & Cost DisciplineClarivate has demonstrated sustained margin expansion via cost efficiency and portfolio disposals, with a ~43% adjusted EBITDA target. Improved margins increase cash conversion and resilience to revenue softness, supporting reinvestment and debt reduction over a multi-quarter horizon.
Bears Say
Revenue DeclineTop-line shrinkage across recent periods signals demand or product-mix pressures that cost cuts alone cannot fix. Persistent revenue declines limit the upside of margin gains and constrain sustainable earnings growth unless organic recurring growth accelerates or successful upsells occur.
Non‑cash Impairment & Net LossesA large non-cash goodwill impairment produced a material quarterly net loss, highlighting prior overpayment or goodwill risks. While accounting, such impairments signal structural recalibration of portfolio value and can persistently pressure reported earnings and ROE metrics through the medium term.
Meaningful LeverageAlthough debt has been coming down, leverage remains sizable relative to equity (D/E ~0.8–0.9). This constrains strategic optionality, increases interest and refinancing sensitivity, and makes sustained deleveraging a multi-quarter imperative to materially improve balance-sheet resilience.
Clarivate News
CLVT FAQ
What was Clarivate’s price range in the past 12 months?
Clarivate lowest stock price was $1.66 and its highest was $4.55 in the past 12 months.
What is Clarivate’s market cap?
Clarivate’s market cap is $1.27B.
When is Clarivate’s upcoming earnings report date?
Clarivate’s upcoming earnings report date is Nov 10, 2026 which is in 100 days.
How were Clarivate’s earnings last quarter?
Clarivate released its earnings results on Jul 29, 2026. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.182 by $0.008.
Is Clarivate overvalued?
According to Wall Street analysts Clarivate’s price is currently Undervalued.
Does Clarivate pay dividends?
Clarivate does not currently pay dividends.
What is Clarivate’s EPS estimate?
Clarivate’s EPS estimate is 0.18.
How many shares outstanding does Clarivate have?
Clarivate has 639,664,000 shares outstanding.
What happened to Clarivate’s price movement after its last earnings report?
Clarivate reported an EPS of $0.19 in its last earnings report, beating expectations of $0.182. Following the earnings report the stock price went down -10.417%.
Which hedge fund is a major shareholder of Clarivate?
Currently, no hedge funds are holding shares in CLVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clarivate Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.93 (37.72% Upside)
$2.93 (37.72% Upside)
Blogger Sentiment
Bullish
CLVT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 273.3K Shares
Last Quarter.
Last Quarter.
News Sentiment
Bearish
Bullish news 33%
Bearish news 67%
Bearish news 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.19%
Trailing 12-Months
Company Description
Clarivate
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.
CLVT Company Deck
CLVT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized clear progress on strategic priorities—AI product launches with early commercial traction, margin expansion, debt reduction and a higher-quality recurring revenue mix driven by portfolio rationalization. These positives were tempered by near-term headwinds including a large non-cash impairment related to the LS&H divestiture, transactional revenue declines, one-time transaction costs that depress free cash flow this year, and FX impacts. Management presented a credible path to sequential organic growth and profitability improvement in the second half, with stronger recurring revenue mix and disciplined capital allocation supporting confidence in longer-term execution.View all CLVT earnings summariesCLVT Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$2.93
▲(37.72% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
6.66% Insiders
8.60% Mutual Funds
11.44% Other Institutional Investors
64.17% Public Companies and
Individual Investors








